NLTX - Neoleukin jumps 7% on Neurogene merger
2023-07-18 06:52:20 ET
Clinical-stage company, Neurogene and Neoleukin Therapeutics ( NASDAQ: NLTX ) to combine the companies in an all-stock transaction.
The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile.
The combined company is expected to operate under the name Neurogene and trade on Nasdaq under the ticker symbol “NGNE”.
In connection with the merger, Neurogene announced an oversubscribed $95M private financing led by new and existing healthcare-dedicated specialist and mutual fund institutional investors.
For further details see:
Neoleukin jumps 7% on Neurogene merger